Brandywine Global Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$6.15M Sell
36,197
-584
-2% -$89.5K 0.04% 338
2025
Q3
$4.85M Sell
36,781
-234,559
-86% -$28.1M 0.03% 383
2025
Q2
$28.8M Sell
271,340
-119,936
-31% -$13M 0.2% 129
2025
Q1
$48.6M Buy
391,276
+9,546
+3% +$1.25M 0.35% 76
2024
Q4
$47M Sell
381,730
-1,390
-0.4% -$164K 0.34% 83
2024
Q3
$42.5M Sell
383,120
-837
-0.2% -$91.7K 0.28% 96
2024
Q2
$41M Sell
383,957
-52,600
-12% -$5.78M 0.31% 87
2024
Q1
$52.6M Buy
436,557
+52,537
+14% +$6.44M 0.38% 70
2023
Q4
$47.2M Buy
384,020
+26,846
+8% +$3.35M 0.38% 78
2023
Q3
$46.2M Sell
357,174
-18,176
-5% -$2.42M 0.41% 75
2023
Q2
$46.5M Sell
375,350
-12,967
-3% -$1.74M 0.39% 77
2023
Q1
$56.8M Buy
388,317
+46,769
+14% +$6.92M 0.46% 60
2022
Q4
$54.4M Buy
341,548
+12,437
+4% +$1.82M 0.42% 65
2022
Q3
$43.9M Sell
329,111
-5,878
-2% -$894K 0.41% 70
2022
Q2
$52.3M Sell
334,989
-5,126
-2% -$789K 0.45% 63
2022
Q1
$52.9M Sell
340,115
-9,944
-3% -$1.44M 0.39% 75
2021
Q4
$44.6M Buy
350,059
+9,170
+3% +$1.21M 0.32% 92
2021
Q3
$44.4M Buy
340,889
+139,619
+69% +$21.1M 0.34% 82
2021
Q2
$35.8M Sell
201,270
-62,905
-24% -$10.9M 0.26% 100
2021
Q1
$43.4M Buy
264,175
+47,074
+22% +$7.75M 0.33% 80
2020
Q4
$35.8M Sell
217,101
-67,375
-24% -$10M 0.3% 88
2020
Q3
$40.6M Sell
284,476
-3,501
-1% -$434K 0.4% 67
2020
Q2
$31.8M Buy
287,977
+48,145
+20% +$5.32M 0.32% 83
2020
Q1
$23.9M Sell
239,832
-123,064
-34% -$15.9M 0.29% 79
2019
Q4
$53.9M Sell
362,896
-22,771
-6% -$3.1M 0.38% 65
2019
Q3
$49.4M Sell
385,667
-6,941
-2% -$930K 0.36% 67
2019
Q2
$56M Buy
392,608
+83,658
+27% +$11.2M 0.39% 64
2019
Q1
$44.2M Buy
308,950
+110,351
+56% +$14.4M 0.31% 81
2018
Q4
$24.6M Buy
198,599
+6,794
+4% +$1.01M 0.18% 118
2018
Q3
$32.2M Sell
191,805
-5,800
-3% -$997K 0.2% 112
2018
Q2
$34M Sell
197,605
-8,300
-4% -$1.36M 0.22% 109
2018
Q1
$31.1M Sell
205,905
-3,171
-2% -$465K 0.2% 113
2017
Q4
$28.2M Sell
209,076
-6,689
-3% -$928K 0.17% 117
2017
Q3
$31.6M Sell
215,765
-2,800
-1% -$423K 0.2% 111
2017
Q2
$34M Sell
218,565
-1,175
-0.5% -$180K 0.22% 98
2017
Q1
$31.9M Sell
219,740
-15,439
-7% -$2.01M 0.2% 101
2016
Q4
$25.6M Sell
235,179
-12,900
-5% -$1.44M 0.16% 122
2016
Q3
$30.1M Sell
248,079
-6,400
-3% -$863K 0.2% 106
2016
Q2
$36M Buy
254,479
+2,969
+1% +$438K 0.24% 95
2016
Q1
$32.8M Buy
251,510
+800
+0.3% +$99.6K 0.21% 99
2015
Q4
$35.2M Sell
250,710
-1,015
-0.4% -$141K 0.22% 98
2015
Q3
$33.4M Buy
251,725
+57,500
+30% +$9.9M 0.22% 100
2015
Q2
$34.2M Buy
194,225
+11,550
+6% +$2.07M 0.21% 98
2015
Q1
$31.6M Buy
182,675
+16,900
+10% +$2.9M 0.2% 99
2014
Q4
$27.1M Buy
+165,775
New +$27.5M 0.18% 113
2013
Q4
Sell
-107,426
Closed -$9.88M 997
2013
Q3
$9.88M Hold
107,426
0.1% 188
2013
Q2
$7.38M Buy
+107,426
New +$6.57M 0.08% 242

Other funds holding JAZZ

Brandywine Global Investment Management's JAZZ Position: Q4 2025 in Review

Brandywine Global Investment Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.6% in Q4 2025, selling an estimated $89.5K and leaving 36,197 shares worth $6.15M. The position accounts for 0.04% of the portfolio, ranked #338.

Brandywine Global Investment Management first reported a position in JAZZ in Q2 2013 and has held it in 47 quarters since. The position peaked at $56.8M in Q1 2023. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Brandywine Global Investment Management held 36,197 shares of Jazz Pharmaceuticals worth $6.15M as of Q4 2025.
  • Brandywine Global Investment Management sold 584 Jazz Pharmaceuticals shares in Q4 2025, an estimated $89.5K.
  • Jazz Pharmaceuticals made up 0.04% of Brandywine Global Investment Management's portfolio in Q4 2025, its #338 holding.
  • Brandywine Global Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
  • Brandywine Global Investment Management's Jazz Pharmaceuticals position peaked at $56.8M in Q1 2023.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.